Dear Editor,

Mass vaccination represented the game changer for the global battle against SARS-CoV-2, an unprecedented infectious threat for the world’s population. Despite the insufficient coverage of low-income countries, more than 9 billion doses of vaccine have been administered to date, providing protection for ~50% of the world’s population. Unfortunately, the vaccination campaign is still in danger by the diffusion of fake news disseminated, mainly through the
web, by anti-science and anti-vaccine movements, although accumulating real-life data [1] confirm the favorable safety profile already demonstrated in phase III clinical trials [2].

It is interesting to note that despite the lack of a robust literature evidence [3], the potential role of vaccines in promoting the development of autoimmunity continues to fascinate researchers. The theoretical basis of this association relies on the possibility of molecular mimicry between components of the vaccine and specific human proteins and the stimulation of aberrant immune responses by adjuvants contained in vaccines [4].

According to the World Health Organization (WHO), adverse events (AEs) after immunization are defined as “any untoward medical occurrence which follows immunization, which does not necessarily have a causal relationship with the usage of the vaccine” [5].

Regarding COVID-19 vaccines, AEs are usually mild and mainly restricted to injection site reactions. Interestingly, amongst systemic AEs, arthralgia is one of the most common [2] and only isolated cases [6–9] of inflammatory rheumatic diseases developed after COVID-19 vaccine administration have been described to date.

To contribute to shed light on this field, in December 2020, we published a web-based survey form and invited all members of the “COVID-19 and autoimmune systemic diseases” collaborative research group to spontaneously submit cases of systemic syndromes of rheumatological interest with onset within four weeks from the administration of the first or second dose of one of the COVID-19 vaccines approved in Italy (BNT162b2, mRNA-1273, AZD1222, Ad26.COV2.S), encountered during routine clinical practice since the beginning of the vaccination campaign in January 2021. Exclusion criteria were a past history of any autoimmune or inflammatory rheumatic disease.

Using this approach, we built a series of 30 individual cases (Table 1) reported by 16 centers belonging to our research network, including 12 (40%) patients with skin vasculitis (40%), four (13.3%) with undifferentiated connective tissue diseases (CTD), two (6.7%) with Sjögren’s syndrome (SjS), one (3.3%) with very early systemic sclerosis (SSc), one (3.3%) with overlap CTD (scleromyositis), two (6.7%) with atypical acrosyndrome [10], one (3.3%) with perinflammatory syndrome, three (10%) with giant cell arteritis (GCA), two (6.7%) with Takayasu’s arteritis (TAK), one (3.3%) with of small vessel vasculitis, and one (3.3%) with cryoglobulinemic vasculitis. Mean time from vaccine administration to clinical manifestations onset was 9 days (range 1–28); most patients 16 (53.3%) received the BNT162b2 vaccine.

After a median follow-up of four weeks, 21 (70%) patients achieved remission or improvement of disease activity according to clinical judgment; on the other hand, seven (23.3%) patients had ongoing active disease (one with skin vasculitis, one with undifferentiated CTD, one with scleromyositis, one with atypical acrosyndrome, one with GCA, one with small vessel vasculitis, and one with perinflammatory syndrome), while three (10%) were lost at follow-up. Most patients (25 out of 30) were initially treated with glucocorticoids (GCs), alone or in combination with disease-modifying antirheumatic drugs (DMARDs), histamine receptor 1 antagonist (H1RA), non-steroidal anti-inflammatory drugs (NSAIDs), intravenous immunoglobulin (IVIG), anakinra, or vasoactive drugs.

In conclusion, despite a clear cause-effect relationship is far to be ascertained, our data suggest that systemic diseases of rheumatological interest may occasionally develop in close temporal association with COVID-19 vaccine administration. Interestingly, 15 patients (50%) developed autoantibodies, suggesting that COVID-19 vaccines may potentially elicit transient or sustained autoimmunity in selected individuals.

However, even if we assume a direct causal relationship, the overall safety of COVID-19 vaccines remains unconcerned and the benefits of vaccination largely outweigh the minimal risks associated with such potential adverse events.
Table 1  Clinical features of post-COVID-19 vaccine syndromes of rheumatological interest. Abbreviations: *aPL*, antiphospholipid antibodies; *ANA*, antinuclear antibodies; *CCA*, common carotid artery; *CPK*, creatine phosphokinase; *CTD*, connective tissue disease; *GCA*, giant cell arteritis; *GCs*, glucocorticoids; *GGO*, ground glass opacities; *HCQ*, hydroxychloroquine; *HRTC*, high-resolution computed tomography; *H1RAs*, histamine receptor 1 antagonists; *IVIG*, intravenous Immunoglobulin; *MTX*, methotrexate; *NSAIDs*, non-steroidal anti-inflammatory drugs; *NVC*, nailfold videocapillaroscopy; *N/A*, not available (lost at follow-up); *PET/CT*, positron emission tomography/computed tomography; *RF*, rheumatoid factor; *RP*, Raynaud’s phenomenon; *TAB*, temporal artery biopsy; *US*, ultrasonography; *18-F FDG*, 18F-fluorodeoxyglucose. *Days between vaccine administration and first symptom of rheumatological interest

| Rheumatological syndrome | Gender, Age | Past COVID-19 Vaccine (days*) | Case description | Autoantibodies | Treatment | Follow-up, weeks | Patient’s status |
|--------------------------|-------------|--------------------------------|------------------|---------------|-----------|-----------------|-----------------|
| **Skin vasculitis**      |             |                                |                  |               |           |                 |                 |
| F, 64                    | No          | mRNA-1273 (2)                  | Palpable purpura of the trunk and upper and lower limbs | None          | GCs       | N/A             | N/A             |
| F, 25                    | No          | BNT162b2 (6)                   | Palpable purpura of the upper and lower limbs, erythematous facial rash | ANA           | GCs, H1RAs | 2               | Remission (drug free) |
| M, 53                    | No          | BNT162b2 (7)                   | Palpable purpura of the upper and lower limbs | None          | GCs, H1RAs | 12              | Remission (drug free) |
| F, 31                    | No          | BNT162b2 (7)                   | Urticarial vasculitis of the lower limbs, erythematous facial rash | None          | GCs       | 6               | Remission (drug free) |
| F, 43                    | No          | AZD1222 (8)                    | Urticarial vasculitis of the upper and lower limbs | None          | GCs       | 4               | Remission (drug free) |
| F, 67                    | No          | BNT162b2 (10)                  | Urticarial vasculitis of the lower limbs, fever | None          | GCs       | 8               | Remission (drug free) |
| F, 68                    | No          | AZD1222 (10)                   | Livedo reticularis of the upper and lower limbs | ANA           | GCs       | 4               | Active           |
| F, 25                    | No          | mRNA-1273 (10)                 | Palpable purpura of the upper and lower limbs | None          | GCs       | 3               | Remission (drug free) |
| F, 77                    | No          | BNT162b2 (10)                  | Palpable purpura of the lower limbs, puffy hands | ANA           | None      | 1               | Remission (drug free) |
| F, 47                    | No          | BNT162b2 (15)                  | Palpable purpura of the lower limbs | RF            | GCs       | 8               | Remission (drug free) |
| F, 29                    | Yes         | BNT162b2 (18)                  | Palpable purpura of the lower limbs | None          | GCs       | 2               | Remission (drug free) |
| M, 38                    | Yes         | BNT162b2 (21)                  | Urticarial vasculitis of the lower limbs, fever | None          | GCs, H1RAs | 4               | Remission (drug free) |
| **Undifferentiated CTD** |             |                                |                  |               |           |                 |                 |
| F, 61                    | No          | BNT162b2 (3)                   | Fever, chest pain, fatigue, arthralgia, myalgia. Laboratory and imaging studies demonstrated inflammatory pleuro-pericardial effusion with no evidence of infection or cancer. Lack of response to GCs/NSAIDs/colchicine treatment; good response to anakinra | ANA, anti-SSA | GCs, NSAIDs, colchicine, anakinra | 4               | Improved |
| M, 50                    | No          | AZD1222 (3)                    | Scarring alopecia, arthralgia of large joints, myalgia | ANA           | GCs       | 8               | Improved |
| M, 45                    | No          | BNT162b2 (5)                   | Chest pain, fatigue, arthralgia, myalgia. Imaging demonstrated pericardial effusion with no evidence of infection or cancer | ANA           | NSAIDs    | N/A             | N/A             |
| M, 32                    | Yes         | BNT162b2 (5)                   | RP with non-specific NVC abnormalities, polyarthritis of large joints, proximal myalgia with normal CPK values, sudden-onset dysphagia | ANA, anti-Jo-1 | GCs, MTX | 4               | Active |

*Days between vaccine administration and first symptom of rheumatological interest.
| Rheumatological syndrome                      | Gender, Age | Past COVID-19 | Vaccine (days*) | Case description                                                                 | Autoantibodies                  | Treatment                      | Follow-up, weeks | Patient’s status |
|-----------------------------------------------|-------------|---------------|----------------|---------------------------------------------------------------------------------|---------------------------------|---------------------------------|------------------|-----------------|
| Sjögren’s syndrome                            | F, 44       | No            | AZD1222 (4)    | Xerostomia, xeroophthalmia, dry cough, dyspnea, RP with non-specific NVC abnormalities. HRTC showed bilateral basal GGO opacities | ANA, anti-SSA                  | GCs                             | 12                | Improved         |
|                                               | F, 62       | No            | AZD1222 (15)   | RP with non-specific NVC abnormalities, xerostomia, xeroophthalmia                | FR, ANA, anti-SSA              | HCQ                             | N/A              | N/A             |
| Very early systemic sclerosis                 | F, 42       | No            | BNT162b2 (20)  | RP with puffy fingers and NVC evidence of early scleroderma pattern, arthralgia, myalgia, fatigue | ANA, anti-centromere           | GCs, HCQ, Felodipine            | 12                | Improved         |
| Overlap CTD (scleromyositis)                  | F, 37       | No            | BNT162b2 (4)   | Sudden-onset muscle pain/weakness with markedly increased CPK levels, RP with NVC evidence of early scleroderma pattern | ANA, anti-Pm/Scl-75, anti-Ku, anti-RNA polymerase III, anti-fibrillarin | GCs, IVIG            | 1                | Active           |
| Atypical acrosyndrome                         | F, 41       | Yes           | MRNA-1273 (2)  | Acrocyanosis with puffy fingers and non-specific NVC abnormalities, arthralgia, myalgia | ANA                             | NSAIDs, aminophosphate          | 4                | Active           |
| F, 37                                         | No           | AZD1222 (28)  |                  | RP with puffy fingers and non-specific NVC abnormalities                           | None                            | NSAIDs, Felodipine              | 12               | Remission (drug free) |
| Iperinflammatory syndrome                     | M, 16       | No            | BNT162b2 (2)   | Pharyngodynia, intermittent erythematous skin rash, arthralgia, flexor tenosynovitis of the fingers, fever. Laboratory tests showed marked increase in inflammatory markers and neutrophil count, liver injury, and hyperferritinemia. PET/CT scan revealed accumulation of 18-FDG in axillar and inguinal lymphnodes, bone marrow, and spleen (enlarged) | None                            | GCs, NSAIDs                     | 3                | Active           |
| Giant cell arteritis                          | M 78        | No            | AZD1222 (1)    | Temporoparietal headache, jaw claudication, fatigue. TAB showed findings consistent with inflammation of the vessel wall and the presence of giant cells. PET/CT scan showed 18F-FDG accumulation in proximal aorta | None                            | GCs                             | 3                | Active           |
|                                               | F, 82       | No            | MRNA-1273 (8)  | Tenderness and swelling of the right temporal artery followed by sudden-onset visual loss | None                            | GCs                             | 6                | Remission        |
|                                               | F, 67       | No            | AZD1222 (14)   | Jaw claudication, fatigue. Temporal artery US showed the typical “halo” sign       | None                            | GCs                             | 6                | Remission        |
| Rheumatological syndrome | Gender, Age | Past COVID-19 | Vaccine (days*) | Case description | Autoantibodies | Treatment | Follow-up, weeks | Patient’s status |
|--------------------------|-------------|---------------|----------------|------------------|----------------|-----------|-----------------|-----------------|
| Takayasu’s arteritis     | F, 31       | No            | BNT162b2 (1)   | Carotidynia, fatigue, night sweating. Doppler US of neck vessels showed diffuse thickening of right CCA; FDG PET-CT scan confirmed accumulation of 18-F FDG in right CCA and both subclavian arteries | None           | GCs       | 8               | Remission       |
|                          | M, 39       | No            | AZD1222 (12)   | Fever, fatigue, erythematous rash of the trunk. PET/CT scan showed 18-F-FDG accumulation in ascending aorta and aortic arch | None           | GCs       | 12              | Remission       |
| Small-vessel vasculitis  | M, 73       | No            | BNT162b2 (5)   | Axonal sensorimotor polyneuropathy, moderate proteinuria, microscopic hematuria, RP with non-specific NVC abnormalities, nodular lesions, and consolidation on HRTC | RF             | GCs       | 4               | Active          |
| Cryoglobulinemic vasculitis | F, 60     | No            | AZD1222 (10)   | Lower limb petechiae, fever, fatigue. Laboratory test showed complement consumption and acute kidney injury with moderate proteinuria | ANA, aPL, cryoglobulins | GCs       | 8               | Remission       |
Declarations

Ethics approval  The study complies with the Declaration of Helsinki. Written informed consent has been obtained from the subjects involved.

Disclosures  None.

References

1. Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R et al (2021) Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med 385(12):1078–1090
2. Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Razizadeh MH, Turner DL et al (2021) Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trials. Vaccines 9(5):467
3. Petras M, Lesna IK, Danova J, Celko AM (2021) Can Vaccination trigger autoimmune disorders? A meta-analysis. Vaccines 9(8):821
4. Segal Y, Shoenfeld Y (2018) Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction. Cell Mol Immunol 15(6):586–594
5. (WHO) WHO. Immunization safety surveillance: guidelines for immunization programme managers on surveillance of adverse events following immunization, 3rd ed. Geneva, Switzerland2016. p. 1–169.
6. An QJ, Qin DA, Pei JX (2021) Reactive arthritis after COVID-19 vaccination. Hum Vaccin Immunother 17(9):2954–2956
7. Baimukhamedov C (2021) Arthritis of the left elbow joint after vaccination against SARS-CoV-2 infection. Int J Rheum Dis 24(9):1218–1220
8. Nune A, Iyengar KP, Goddard C, Ahmed AE (2021) Multisystem inflammatory syndrome in an adult following the SARS-CoV-2 vaccine (MIS-V). BMJ case reports 14(7):e243888
9. Ursini F, Ruscitti P, Iagnocco A, Ferri C, Giacomelli R et al (2021) Isolated “puffy hands” following COVID-19: clue to a long-term capillary leakage syndrome? Clin Rheumatol 40(9):3863–3864

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
17 Clinical Immunology Outpatient Clinic, Department of Medicine, “Luigi Vanvitelli” University of Campania, Napoli, Italy

18 Rheumatology Unit, Azienda Ospedaliero Universitaria Città Della Salute E Della Scienza Di Torino, Torino, Italy

19 Academic Rheumatology Centre, MFRU, Dipartimento Scienze Cliniche E Biologiche, Università Degli Studi Di Torino, Torino, Italy

20 Unit of Allergology, Immunology, Rheumatology, Università Campus Bio-Medico Di Roma, Roma, Italy

21 Rheumatology Unit, University of Modena and Reggio Emilia, Modena, Italy